Brief: European Medicines Agency Grants Orphan Drug Designation For Moleculin's Treatment Of Acute Myeloid Leukemia
18/04/2024 14:19
April 18 (Reuters) - Moleculin Biotech Inc MBRX.O :
* EUROPEAN MEDICINES AGENCY (EMA) GRANTS ORPHAN DRUG
DESIGNATION
FOR MOLECULIN'S TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
Source text for Eikon: ID:nPnzV7nQa
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM